Press Release

(September 13, 2022) - TriLink now offers GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate, a critical raw material for mRNA manufacturing, allowing researchers to accelerate their drug discovery and development timelines and US-source their supply chain.

SAN DIEGO - TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5’-Triphosphate (N1meΨTP), a modified nucleoside-triphosph...

(July 6, 2022) - Appoints Dr. Kate Broderick as Senior Vice President of Research and Development.

SAN DIEGO, — July 6, 2022 — TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, today announced that Kate Broderick, Ph.D., has joined the Company as Senior Vice President of Research and Development.  In this newly created role, Kate will have responsibility for leading TriLink’s research and development strategy and scientific direction. S...

(May 24, 2022) - DOD to fund planned manufacturing expansion and to prepare the U.S. for a rapid response to the next pandemic as part of Industrial Base Expansion

SAN DIEGO, — May  24, 2022 — TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI), and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, today announced a Cooperative Agreement with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-C...

(October 4, 2021) - EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials

SAN DIEGO, October 4, 2021 — TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today that it expects to supply its proprietary CleanCap® ...

(August 3, 2021) - TriLink enables Chula VRC to take its Covid-19 vaccine into a First in Human (FIH) phase 1 clinical trial in Thailand with mRNA manufacturing process development and its proprietary mRNA capping technology, ushering a much-needed vaccine into economically developing countries.

SAN DIEGO — TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics ap...

(March 15, 2021) - New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing.

SAN DIEGO — Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTec...

(August 25, 2020) - Second manufacturing expansion within a year will help meet global demand for research, clinical and GMP grade raw materials as well as research and clinical grade APIs to include mRNA, self-amplifying RNA and plasmid DNA

SAN DIEGO, Calif. — Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriL...

(April 27, 2020) - SAN DIEGO –TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced today that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA (saRNA) for COVID-19 vaccine development. The vaccine development program is led by Professor Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Infectious Disease at ...

In the News

At Least 6 Companies Working on COVID Vaccines in San Diego

(10 News San Diego: June 24, 2020) - At least six companies are working on COVID-19 vaccine candidates in San Diego, all within a 1.5-mile radius of where the I-5 and I-805 split. Locally, the farthest along appears to be Inovio Pharmaceuticals, which plans to launch a Phase 2 trial next month, potentially with a simultaneous Phase 3 trial. A Phase 3 trial is the final step in vaccine testing, with thousands of participants. The company is develop...

Coronavirus: Human Trial of New Vaccine Begins in UK

(BBC News: June 24, 2020) - Volunteers have begun being immunised with a new UK coronavirus vaccine. About 300 people will have the vaccine over the coming weeks, as part of a trial led by Prof Robin Shattock and his colleagues, at Imperial College London. Tests in animals suggest the vaccine is safe and triggers an effective immune response. Experts at Oxford University have already started human trials. The trials are among many across the...

Sara Michelmore
MacDougall
Phone: +1 781-235-3060
Email: [email protected]

""